This longitudinal study will allow us to systematically analyse the performance of plasma NfL in combination with other biomarkers reflecting different pathophysiological processes in PD (e.g. plasma tau, alpha-synuclein and uric acid etc), which may improve its discriminatory performance. Here, SNCA is linked to Parkinson disease.